골관절염 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약물 유형별, 해부학적 구조별, 투여 경로별, 판매 채널별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Osteoarthritis Therapeutics Market Growth & Trends:

The global osteoarthritis therapeutics market size is expected to reach USD 13.57 billion by 2030, registering a CAGR of 6.89% from 2025 to 2030, according to a new report by Grand View Research, Inc. The osteoarthritis therapeutics market is on the rise, driven by an increase in OA cases, especially among the aging population. In the U.S. alone, there are over 32.5 million OA patients, highlighting the demand for effective treatments. Ongoing research and development efforts are focused on creating new therapies, with a particular emphasis on understanding the disease and developing solutions to address its challenges.

Managing OA proves difficult owing to its dense tissue structure, but the introduction of novel drugs such as intra-articular drug administration has accelerated the development of targeted drug delivery. Researchers are actively exploring disease-modifying drugs and bioadaptive carriers to enhance the development of innovative osteoarthritis treatments. Market players are taking initiatives to contribute to market expansion, as seen with OrthoTrophix, Inc. presenting clinical data and a registration plan for TPX-100 for knee osteoarthritis at BIO 2022.

In addition, significant efforts are being made by key pharmaceutical companies and research institutes in realm of research and development, especially for disease-modifying osteoarthritis drugs. For instance, BioSenic's Phase 3 data presentation at the 2024 OARSI World Congress showcased the efficacy of JTA-004 in treating severe inflammatory knee osteoarthritis. The post hoc analysis concluded that JTA-004 is both safe and effective, offering targeted pain management for this specific subtype of condition. These advancements in targeted drug delivery and disease-modifying drugs, as demonstrated by presentations and positive trial results, are contributing to the expansion of the market for novel osteoarthritis treatments.

Moreover, the market for OA is experiencing significant growth owing to the introduction of personalized medications such as Bisphosphonates (anti-resorptive drugs) and Synvisc-ONE injection. In addition, pharmaceutical companies and research institutions are actively engaged in developing personalized treatments and cell-based therapies for OA. In December 2023, researchers at Columbia University made a breakthrough discovery of stem cells in adult mice capable of maintaining healthy cartilage in joints, with their decline contributing to OA development due to aging and injury.

Investing in this sector offers companies the opportunity to capitalize on evolving demands, thus gaining a competitive advantage. By leading innovative medication development, companies establish themselves as frontrunners, solidifying their position in the market. The advent of personalized OA medications and advancements in cell-based therapies are key drivers of market expansion, empowering companies to emerge as leaders in the field.

Osteoarthritis Therapeutics Market Report Highlights:

• Based on drug type, the viscosupplementation agents segment accounted for the largest share of 37.06% in 2024 and is expected to grow at the fastest CAGR over the forecast period due to their adoption and efficacy in managing OA symptoms.
• Based on anatomy, the knee osteoarthritis (KOA) segment held a dominant share of 42.07% in 2024. KOA is one of the most common forms of chronic articular disease and OA worldwide and is characterized by high disability & morbidity rates.
• Based on route of administration, the parenteral route segment held a dominant share in 2024 and is expected to grow at a CAGR of 7.57% over the forecast period due to its efficacy for certain therapies, better pharmacokinetics and pharmacodynamics, ease of administration, and higher projected growth rate.
• Prescription drugs are poised to maintain dominance in the osteoarthritis therapeutics market' sales Channel segment in 2024.
• Based on end-use, the hospital pharmacies segment held a dominant share in 2024, accounting for 47.50%.
• North America osteoarthritis therapeutics market dominated the global industry and accounted for a 37.31% share in 2024. The North American market maintains its dominance due to several factors, including a high prevalence of obesity and supportive government policies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
  • 1.2.2. Anatomy
  • 1.2.3. Route of Administration
  • 1.2.4. Sales Channel
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug type outlook
  • 2.2.2. Anatomy outlook
  • 2.2.3. Route of administration outlook
  • 2.2.4. Sales channel outlook
  • 2.2.5. End use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Osteoarthritis Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High Prevalence of Osteoarthritis
    • 3.2.1.2. Growing Aging Population
    • 3.2.1.3. Technological Advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Side Effects and Adverse Reactions
    • 3.2.2.2. High cost of osteoarthritis therapeutics drugs
• 3.3. Osteoarthritis Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Osteoarthritis Therapeutics Market: Drug Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Osteoarthritis Therapeutics Market by Drug Type Outlook
• 4.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
• 4.4. Viscosupplementation Agents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Nonsteroidal Anti-inflammatory Drugs
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.1. Naproxen
      • 4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.2. Aspirin
      • 4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.3. Diclofenac
      • 4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.4. Ibuprofen
      • 4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.5. Celecoxib
      • 4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.6. Meloxicam
      • 4.5.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.7. Piroxicam
      • 4.5.1.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.8. Ketoprofen
      • 4.5.1.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.1.9. Other NSAIDs
      • 4.5.1.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Analgesics
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.1.1. Duloxetine
        • 4.5.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.2.1.2. Acetaminophen
        • 4.5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Corticosteroids
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Osteoarthritis Therapeutics Market: Anatomy Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 5.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Anatomy, 2018 to 2030 (USD Million)
• 5.4. Knee Osteoarthritis
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hip Osteoarthritis
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Hand Osteoarthritis
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Osteoarthritis Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 6.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Parenteral Route
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.1. Hyaluronic Acid Injections
      • 6.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.2. Corticosteroid Injections
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.3. Platelet-rich Plasma (PRP) Injections
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.4. Placental Tissue Matrix (PTM) Injections
      • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.5. Acetylsalicylic Acid (ASA) Injections
      • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.1.6. Others
      • 6.4.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Topical Route
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Oral Route
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Osteoarthritis Therapeutics Market: Sales Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 7.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
• 7.4. Prescription Drugs
  • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Over-the-Counter Drugs
  • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Osteoarthritis Therapeutics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Osteoarthritis Therapeutics Market Movement Analysis
• 8.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by End Use 2018 to 2030 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Others
  • 8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Osteoarthritis Therapeutics Market: Regional Estimates & Trend Analysis by

• 9.1. Regional Market Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2024
  • 10.3.4. Sanofi SA
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. GlaxoSmithKline plc
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Pfizer Inc.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Bayer AG
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Zimmer Biomet
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Novartis AG
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Anika Therapeutics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Assertio Therapeutics, Inc.
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Bioventus
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Ferring Pharmaceuticals Inc.
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives